VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q42266131 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010712.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q42266131‏
024 ‎‡a 0000-0003-3750-9233‏ ‎‡2 orcid‏
024 ‎‡a 55520863700‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q42266131‏
100 0 ‎‡a Maria Giner-Soriano‏ ‎‡9 sl‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a Maria Giner-Soriano‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Maria Giner-Soriano‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400 0 ‎‡a Maria Giner-Soriano‏ ‎‡c investigadora‏ ‎‡9 es‏
400 0 ‎‡a Maria Giner-Soriano‏ ‎‡c investigadora‏ ‎‡9 ast‏
670 ‎‡a Author's Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records‏
670 ‎‡a Author's Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators‏
670 ‎‡a Author's [Bibliometric analysis of female authorship in original articles in the journal ATENCIÓN PRIMARIA]‏
670 ‎‡a Author's Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment‏
670 ‎‡a Author's Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany‏
670 ‎‡a Author's Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.‏
670 ‎‡a Author's Drug Therapy for Rate and Rhythm Control in Nonvalvular Atrial Fibrillation: A Cross-sectional Study With Electronic Health Records in a Primary Care Cohort‏
670 ‎‡a Author's Effective treatment of a highly active antiretroviral regimen through jejunostomy‏
670 ‎‡a Author's Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database.‏
670 ‎‡a Author's Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany‏
670 ‎‡a Author's [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score]‏
670 ‎‡a Author's Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database‏
670 ‎‡a Author's Efficacy and safety of topical application of 15% and 10% potassium hydroxide for the treatment of Molluscum contagiosum.‏
670 ‎‡a Author's Impact of Medication Adherence on Mortality and Cardiovascular Morbidity: Protocol for a Population-Based Cohort Study.‏
670 ‎‡a Author's Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study‏
670 ‎‡a Author's Narcolepsy and adjuvanted pandemic influenza A‏
670 ‎‡a Author's Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment‏
670 ‎‡a Author's Neumonías adquiridas en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica tratados con corticoides inhalados u otros broncodilatadores. Estudio PNEUMOCORT‏
670 ‎‡a Author's Randomized placebo-controlled clinical trial on efficacy and safety of topical 10% Potassium hydroxide for molluscum contagiosum treatment in children‏
670 ‎‡a Author's Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources‏
670 ‎‡a Author's Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.‏
670 ‎‡a Author's The prevalence of narcolepsy in Catalunya‏
670 ‎‡a Author's The prevalence of narcolepsy in Catalunya (Spain).‏
670 ‎‡a Author's Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: A study in three European data sources‏
909 ‎‡a (orcid) 0000000337509233‏ ‎‡9 1‏
909 ‎‡a (scopus) 55520863700‏ ‎‡9 1‏
919 ‎‡a drugtherapyforrateandrhythmcontrolinnonvalvularatrialfibrillationacrosssectionalstudywithelectronichealthrecordsinaprimarycarecohort‏ ‎‡A Drug Therapy for Rate and Rhythm Control in Nonvalvular Atrial Fibrillation: A Cross-sectional Study With Electronic Health Records in a Primary Care Cohort‏ ‎‡9 1‏
919 ‎‡a effectivenessofriskminimizationmeasuresfortheuseofcilostazolinunitedkingdomspainswedenandgermany‏ ‎‡A Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany‏ ‎‡9 1‏
919 ‎‡a effectivenessandsafetyofdrugsusedforstrokepreventioninacohortofnonvalvularatrialfibrillationpatientsfromaprimarycareelectronicdatabase‏ ‎‡A Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database.‏ ‎‡9 1‏
919 ‎‡a effectivetreatmentofahighlyactiveantiretroviralregimenthroughjejunostomy‏ ‎‡A Effective treatment of a highly active antiretroviral regimen through jejunostomy‏ ‎‡9 1‏
919 ‎‡a impactofmedicationadherenceonmortalityandcardiovascularmorbidityprotocolforapopulationbasedcohortstudy‏ ‎‡A Impact of Medication Adherence on Mortality and Cardiovascular Morbidity: Protocol for a Population-Based Cohort Study.‏ ‎‡9 1‏
919 ‎‡a incidenceratesofnarcolepsydiagnosesintaiwancanadaandeuropetheuseofstatisticalsimulationtoevaluatemethodsfortherapidassessmentofpotentialsafetyissuesonapopulationlevelinthesomniastudy‏ ‎‡A Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study‏ ‎‡9 1‏
919 ‎‡a narcolepsyandadjuvantedpandemicinfluenzaa‏ ‎‡A Narcolepsy and adjuvanted pandemic influenza A‏ ‎‡9 1‏
919 ‎‡a narcolepsyandadjuvantedpandemicinfluenzaah1n12009vaccinesmulticountryassessment‏ ‎‡A Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment‏ ‎‡9 1‏
919 ‎‡a neumoniasadquiridasenlacomunidadenpacientesconenfermedadpulmonarobstructivacronicatratadosconcorticoidesinhaladosuotrosbroncodilatadoresestudiopneumocort‏ ‎‡A Neumonías adquiridas en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica tratados con corticoides inhalados u otros broncodilatadores. Estudio PNEUMOCORT‏ ‎‡9 1‏
919 ‎‡a randomizedplacebocontrolledclinicaltrialonefficacyandsafetyoftopical10potassiumhydroxideformolluscumcontagiosumtreatmentinchildren‏ ‎‡A Randomized placebo-controlled clinical trial on efficacy and safety of topical 10% Potassium hydroxide for molluscum contagiosum treatment in children‏ ‎‡9 1‏
919 ‎‡a riskofacuteliverinjuryinagomelatineandotherantidepressantusersin4europeancountriesacohortandnestedcasecontrolstudyusingautomatedhealthdatasources‏ ‎‡A Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources‏ ‎‡9 1‏
919 ‎‡a safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase‏ ‎‡A Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database.‏ ‎‡9 1‏
919 ‎‡a prevalenceofnarcolepsyincatalunya‏ ‎‡A The prevalence of narcolepsy in Catalunya‏ ‎‡9 1‏
919 ‎‡a prevalenceofnarcolepsyincatalunyaspain‏ ‎‡A The prevalence of narcolepsy in Catalunya (Spain).‏ ‎‡9 1‏
919 ‎‡a validityoficd9andicd10codesusedtoidentifyacuteliverinjuryastudyin3europeandatasources‏ ‎‡A Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: A study in three European data sources‏ ‎‡9 1‏
919 ‎‡a efficacyandsafetyoftopicalapplicationof15and10potassiumhydroxideforthetreatmentofmolluscumcontagiosum‏ ‎‡A Efficacy and safety of topical application of 15% and 10% potassium hydroxide for the treatment of Molluscum contagiosum.‏ ‎‡9 1‏
919 ‎‡a annualcostsattributedtoatrialfibrillationmanagementcrosssectionalstudyofprimaryhealthcareelectronicrecords‏ ‎‡A Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records‏ ‎‡9 1‏
919 ‎‡a effectivenesssafetyandcostsofthromboembolicpreventioninpatientswithnonvalvularatrialfibrillationphase1escfaprotocolstudyandbaselinecharacteristicsofacohortfromaprimarycareelectronicdatabase‏ ‎‡A Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database‏ ‎‡9 1‏
919 ‎‡a antidepressantuseindenmarkgermanyspainandswedenbetween2009and2014incidenceandcomorbiditiesofantidepressantinitiators‏ ‎‡A Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators‏ ‎‡9 1‏
919 ‎‡a bibliometricanalysisoffemaleauthorshipinoriginalarticlesinthejournalatencionprimaria‏ ‎‡A [Bibliometric analysis of female authorship in original articles in the journal ATENCIÓN PRIMARIA]‏ ‎‡9 1‏
919 ‎‡a characteristicsofapixabantreatedpatientsevaluationofthedoseprescribedandthepersistenceoftreatment‏ ‎‡A Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment‏ ‎‡9 1‏
919 ‎‡a studyofcohortsmatchedbypropensityscore‏ ‎‡A Study of cohorts matched by Propensity score]‏ ‎‡9 1‏
919 ‎‡a characterizationofnewusersofcilostazolintheukspainswedenandgermany‏ ‎‡A Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany‏ ‎‡9 1‏
919 ‎‡a dabigatranandvitaminkantagonistsuseinnaivepatientswithnonvalvularatrialfibrillationacrosssectionalstudyofprimarycarebasedelectronichealthrecords‏ ‎‡A Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 BNE|XX4940529‏
996 ‎‡2 LC|nr2003016956‏
996 ‎‡2 NTA|113947828‏
996 ‎‡2 SUDOC|059090170‏
996 ‎‡2 BLBNB|000274457‏
996 ‎‡2 LC|nr2007000185‏
996 ‎‡2 BNF|14794786‏
996 ‎‡2 ISNI|0000000060911288‏
996 ‎‡2 BNE|XX1125697‏
996 ‎‡2 BNC|981058513265806706‏
996 ‎‡2 BNE|XX1234994‏
996 ‎‡2 BNE|XX1474099‏
996 ‎‡2 BNE|XX950279‏
996 ‎‡2 BNE|XX1020861‏
996 ‎‡2 SUDOC|143157892‏
996 ‎‡2 LC|n 82050285‏
996 ‎‡2 SUDOC|233790837‏
996 ‎‡2 BNE|XX1582306‏
996 ‎‡2 BNC|981058512541806706‏
996 ‎‡2 DNB|132724839‏
996 ‎‡2 BIBSYS|11028241‏
996 ‎‡2 DNB|1049398688‏
996 ‎‡2 BNE|XX1098982‏
996 ‎‡2 BNF|12973232‏
996 ‎‡2 DNB|1057407208‏
996 ‎‡2 LC|no2019137799‏
996 ‎‡2 BNE|XX847726‏
996 ‎‡2 BNC|981058517347906706‏
996 ‎‡2 BNF|12403760‏
996 ‎‡2 CAOONL|ncf10705725‏
996 ‎‡2 ISNI|0000000116135442‏
996 ‎‡2 BNC|981058514150706706‏
996 ‎‡2 NYNYRILM|31897‏
996 ‎‡2 BNE|XX941117‏
996 ‎‡2 W2Z|90673421‏
996 ‎‡2 LC|no2010144523‏
996 ‎‡2 BNE|XX5263622‏
996 ‎‡2 PLWABN|9812371875505606‏
996 ‎‡2 ISNI|0000000360598991‏
996 ‎‡2 BNC|981058516297306706‏
996 ‎‡2 BNE|XX5330582‏
996 ‎‡2 ISNI|000000007996630X‏
996 ‎‡2 SUDOC|083634991‏
996 ‎‡2 LC|n 2009033702‏
996 ‎‡2 LC|ns2016001511‏
996 ‎‡2 BNE|XX1674868‏
996 ‎‡2 ISNI|0000000111670841‏
996 ‎‡2 SUDOC|276976320‏
996 ‎‡2 BNC|981058515016406706‏
996 ‎‡2 SUDOC|253994381‏
996 ‎‡2 LC|n 2020184797‏
996 ‎‡2 BNCHL|10000000000000000090185‏
996 ‎‡2 ISNI|0000000059276547‏
996 ‎‡2 ISNI|0000000121232757‏
996 ‎‡2 ISNI|0000000111695395‏
996 ‎‡2 ISNI|0000000114718564‏
996 ‎‡2 BNC|981058610871906706‏
996 ‎‡2 LC|no2003061984‏
996 ‎‡2 BNE|XX841797‏
996 ‎‡2 ISNI|0000000059214055‏
996 ‎‡2 BNE|XX4785072‏
996 ‎‡2 DNB|1057674265‏
996 ‎‡2 BNE|XX1146975‏
996 ‎‡2 BAV|495_42690‏
996 ‎‡2 ISNI|000000006050392X‏
996 ‎‡2 PTBNP|245218‏
996 ‎‡2 BNC|981058516274306706‏
996 ‎‡2 SUDOC|170441911‏
996 ‎‡2 RERO|A009434353‏
996 ‎‡2 BNE|XX5060162‏
996 ‎‡2 ISNI|000000011738781X‏
996 ‎‡2 BNE|XX4772543‏
996 ‎‡2 ISNI|0000000081038406‏
996 ‎‡2 ISNI|0000000059733939‏
996 ‎‡2 DNB|1057697257‏
996 ‎‡2 ISNI|0000000060356405‏
996 ‎‡2 BNE|XX1047814‏
996 ‎‡2 SZ|1057407208‏
996 ‎‡2 LC|ns2021000614‏
996 ‎‡2 ICCU|CAGV182894‏
996 ‎‡2 BNE|XX1424594‏
996 ‎‡2 DNB|1056185244‏
996 ‎‡2 BNE|XX924377‏
996 ‎‡2 ISNI|000000011609189X‏
996 ‎‡2 LC|n 98019235‏
996 ‎‡2 ISNI|0000000060735712‏
996 ‎‡2 CAOONL|ncf11463125‏
996 ‎‡2 ISNI|0000000060167524‏
996 ‎‡2 ISNI|0000000140785533‏
996 ‎‡2 NTA|160830915‏
996 ‎‡2 J9U|987007424694105171‏
996 ‎‡2 NUKAT|n 2004094247‏
996 ‎‡2 ISNI|0000000060685292‏
996 ‎‡2 BNC|981058522097006706‏
996 ‎‡2 BNE|XX1126623‏
996 ‎‡2 ISNI|0000000054507975‏
996 ‎‡2 RERO|A011817825‏
996 ‎‡2 BNE|XX6205304‏
996 ‎‡2 SUDOC|254990215‏
996 ‎‡2 RERO|A005638027‏
996 ‎‡2 LC|ns2024001153‏
996 ‎‡2 NUKAT|n 2005094869‏
996 ‎‡2 LC|n 96020655‏
996 ‎‡2 BNE|XX941418‏
996 ‎‡2 DNB|1213926998‏
996 ‎‡2 BNF|17033034‏
996 ‎‡2 ISNI|0000000078243185‏
996 ‎‡2 LC|no2010195454‏
996 ‎‡2 LC|n 2001095772‏
996 ‎‡2 NYNYRILM|360311‏
996 ‎‡2 DNB|1061439011‏
996 ‎‡2 DE633|pe30019631‏
996 ‎‡2 BNE|XX1209474‏
996 ‎‡2 BNC|981058525740806706‏
996 ‎‡2 DNB|1056430605‏
996 ‎‡2 LC|n 91001292‏
996 ‎‡2 DNB|17297948X‏
996 ‎‡2 LC|n 98050916‏
996 ‎‡2 BIBSYS|90673421‏
996 ‎‡2 BNE|XX1095759‏
996 ‎‡2 NII|DA08315162‏
996 ‎‡2 LC|no2008041291‏
996 ‎‡2 BNC|981058612228806706‏
996 ‎‡2 BNE|XX1778218‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏